Baseline characteristics and outcome measures
| Characteristic . | Value . |
|---|---|
| Baseline characteristics of 28 qualified patients* | |
| Median age, y (range) | 40 (19-68) |
| Sex, no. (%) | |
| Male | 20 (71.4) |
| Female | 8 (28.6) |
| Disease involvement,† no. (%) | |
| Infradiaphragmatic | 7/25 (28.0) |
| Supradiaphragmatic | 18/25 (72.0) |
| Remission status after lymph node biopsy,‡ no. (%) | |
| CR | 9/23 (39.1) |
| Residual disease | 14/23 (60.9) |
| Response to treatment§ | |
| Overall response, no. (%) | 28 (100.0) |
| CR/CRu | 24 (85.7) |
| Partial remission | 4 (14.3) |
| Tumor events,‖ no. (%) | |
| First relapse,¶ no. (%) | 7 (25.0) |
| Secondary malignancies,# no. (%) | 2 (7.1) |
| NLPHL relapse according to the remission status after lymph node biopsy‡ | |
| CR, no. (%) | 0/9 (0) |
| Residual disease, no. (%) | 7/14 (50.0) |
| Survival analyses | |
| Median observation time, mo (range) | 42.7 (38.0-44.5) |
| Progression-free survival, %, point estimate (CI) | |
| 1-year | 96.4 (89.6-100.0) |
| 2-year | 85.3 (71.9-98.6) |
| 3-year | 81.4 (66.6-96.1) |
| 4-year | 77.1 (60.9-93.3) |
| Overall survival | 100% |
| Characteristic . | Value . |
|---|---|
| Baseline characteristics of 28 qualified patients* | |
| Median age, y (range) | 40 (19-68) |
| Sex, no. (%) | |
| Male | 20 (71.4) |
| Female | 8 (28.6) |
| Disease involvement,† no. (%) | |
| Infradiaphragmatic | 7/25 (28.0) |
| Supradiaphragmatic | 18/25 (72.0) |
| Remission status after lymph node biopsy,‡ no. (%) | |
| CR | 9/23 (39.1) |
| Residual disease | 14/23 (60.9) |
| Response to treatment§ | |
| Overall response, no. (%) | 28 (100.0) |
| CR/CRu | 24 (85.7) |
| Partial remission | 4 (14.3) |
| Tumor events,‖ no. (%) | |
| First relapse,¶ no. (%) | 7 (25.0) |
| Secondary malignancies,# no. (%) | 2 (7.1) |
| NLPHL relapse according to the remission status after lymph node biopsy‡ | |
| CR, no. (%) | 0/9 (0) |
| Residual disease, no. (%) | 7/14 (50.0) |
| Survival analyses | |
| Median observation time, mo (range) | 42.7 (38.0-44.5) |
| Progression-free survival, %, point estimate (CI) | |
| 1-year | 96.4 (89.6-100.0) |
| 2-year | 85.3 (71.9-98.6) |
| 3-year | 81.4 (66.6-96.1) |
| 4-year | 77.1 (60.9-93.3) |
| Overall survival | 100% |
NLPHL stage IA without risk factor (large mediastinal mass, extranodal disease, elevated erythrocyte sedimentation rate, involvement of 3 or more nodal areas). One patient was not qualified because of diffuse large B-cell lymphoma diagnosis in addition to NLPHL at baseline.
Information is missing for 3 patients.
Information is missing for 5 patients.
Tumor status according to CT-based restaging 4 weeks after end of treatment.
Median observation time is 43 months.
Times to relapse since first NLPHL diagnosis were 9.6, 13.2, 14.4, 21.6, 26.4, 37.2, and 49.2 months, respectively.
Solid tumors: 1 adenocarcinoma of the colon 2 years after NLPHL diagnosis (male patient, 48 years) and 1 breast cancer 4 years after NLPHL diagnosis (female patient, 62 years).